Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Exenatide × Gastrointestinal × Clear all

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 166 Bevacizumab 140 Fluorouracil 137 Gemcitabine 120 Capecitabine 117 Leucovorin 96 pembrolizumab 95 Cisplatin 82 Drug Therapy 75 Radiotherapy 71 Irinotecan 71 durvalumab 63 Paclitaxel 58 Cetuximab 58 130-nm albumin-bound paclitaxel 58 lenvatinib 56 Specimen Handling 56 sintilimab 54 Folfox protocol 51 tislelizumab 50 Magnetic Resonance Spectroscopy 47 Blood Specimen Collection 47 Nivolumab 46 Biopsy 44 atezolizumab 42 Surgical Procedures, Operative 40 Taxes 35 Albumin-Bound Paclitaxel 35 Carboplatin 32 HMPL-013 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡